Mursla Bio
Mursla Bio offers an organ-specific blood test that detects early liver cancer in high-risk patients by reading extracellular vesicle (EV) signals. The company physically isolates liver-derived EVs from blood and performs multiomic profiling across proteomics, small RNA (miRNA) and mRNA sequencing, then applies AI/ML models to derive diagnostic biomarkers and risk scores. It operates as an AI precision diagnostics company providing a laboratory-developed test (LDT) and a SaaS-enabled platform for biomarker discovery, assay development, and clinical deployment. Key technologies include organ-specific EV isolation, proteomics, small RNA sequencing, multiomic integration, and machine learning models validated in multi-center clinical studies. Mursla Bio is advancing EvoLiver toward commercial LDT launch for surveillance of patients at high risk of liver cancer.
Mursla Bio
Mursla Bio offers an organ-specific blood test that detects early liver cancer in high-risk patients by reading extracellular vesicle (EV) signals. The company physically isolates liver-derived EVs from blood and performs multiomic profiling across proteomics, small RNA (miRNA) and mRNA sequencing, then applies AI/ML models to derive diagnostic biomarkers and risk scores. It operates as an AI precision diagnostics company providing a laboratory-developed test (LDT) and a SaaS-enabled platform for biomarker discovery, assay development, and clinical deployment. Key technologies include organ-specific EV isolation, proteomics, small RNA sequencing, multiomic integration, and machine learning models validated in multi-center clinical studies. Mursla Bio is advancing EvoLiver toward commercial LDT launch for surveillance of patients at high risk of liver cancer.